CytoDyn and NIH of Mexico to conduct COVID-19 Phase 3 trial

CytoDyn (OTCQB:CYDY) has entered into a Memorandum of Understanding (MoU) with the Coordinating Commission of the National Institutes of Health and High Specialty Hospitals of Mexico (NIH) to conduct a COVID-19 clinical trial with leronlimab for severe and critically ill patients, with the potential to collaborate on additional COVID-19 trials.

Under MoU, CytoDyn will supply leronlimab at its expense, and both parties will proceed expeditiously to complete the mutually agreed protocol for this clinical trial.

The Phase 3 trial is expected to enroll only 25 patients.

https://seekingalpha.com/news/3586774-cytodyn-and-nih-of-mexico-to-conduct-covidminus-19-phase-3-trial